



Enhancing Psoriasis Management with Biologic Agents: A Transformative Paradigm Shift

Monica Trifitriana*

Medical Doctor, Sriwijaya University, Indonesia

*Corresponding author: Monica Trifitriana, Medical Doctor, Sriwijaya University, Indonesia, Tel: 0822-89610360; Email: mtrifitriana18@gmail.com

Editorial

Volume 9 Issue 1

Received Date: February 24, 2024

Published Date: March 01, 2024

DOI: 10.23880/cdoaj-16000321

Introduction

Psoriasis, a chronic inflammatory skin condition, poses significant challenges to patients and clinicians due to its unpredictable course and varied clinical manifestations [1]. Conventional therapies often provide limited efficacy and are associated with adverse effects [2]. However, the emergence of biologic agents has revolutionized psoriasis management by specifically targeting key inflammatory pathways, offering remarkable efficacy and safety profiles [2,3].

Understanding Biologic Agents

Enter biologic agents, a revolutionary class of drugs transforming the psoriasis treatment landscape.³ Biologic agents are genetically engineered proteins derived from living organisms. They selectively inhibit specific components of the immune system involved in the pathogenesis of psoriasis, such as tumour necrosis factor-alpha (TNF- α), interleukin-17 (IL-17), and interleukin-23 (IL-23), thereby modulating the inflammatory cascade responsible for disease progression.⁴ Among the most notable biologics is adalimumab, which inhibits tumour necrosis factor-alpha (TNF-alpha), a key cytokine implicated in psoriasis pathogenesis.

Efficacy Profile

Clinical trials have demonstrated the superior efficacy of biological agents compared to traditional systemic therapies and topical treatments [4,5]. These agents achieve rapid and sustained clearance of psoriatic lesions, improving quality of life and reducing patient disease burden. Moreover, biologics have shown efficacy across various psoriasis phenotypes, including plaque, guttate, pustular, and erythrodermic

psoriasis [5].

Safety Considerations

While biological agents offer significant benefits, safety remains a crucial consideration. Adverse events such as injection site reactions, upper respiratory tract infections, and rare serious infections may occur [6]. Long-term safety data are monitored to assess the risk of immunogenicity, malignancies, and cardiovascular events associated with prolonged biologic therapy [7].

Personalized Treatment Approach

The heterogeneity of psoriasis necessitates a personalized treatment approach. Clinicians must consider disease severity, comorbidities, patient preferences, and treatment goals when selecting biologic therapy.¹ Tailoring treatment regimens based on individual patient characteristics optimizes therapeutic outcomes and enhances patient adherence [8].

Challenges and Future Directions

Despite the remarkable success of biological agents, challenges persist, including accessibility, cost, and long-term sustainability. Addressing these challenges requires collaborative efforts among healthcare providers, policymakers, and pharmaceutical companies to ensure equitable access to these innovative therapies. Additionally, on-going research aims to identify novel therapeutic targets and optimize treatment algorithms to improve outcomes in psoriasis management further.

Conclusion

Biologic agents represent a ground breaking advancement in the management of psoriasis, offering unparalleled efficacy and transforming the treatment landscape. By targeting specific immune pathways implicated in disease pathogenesis, biologics provide personalized therapeutic options that significantly improve patient outcomes and quality of life. Continued research and collaboration are essential to address challenges and further optimize the use of biological agents in psoriasis care.

References

1. Magina S, Felipe P (2021) Pathophysiology of moderate to severe plaque psoriasis: Anti IL-17 towards disease modification. *Drugs Today* 57(5): 347-357.
2. Suarez FM, Fuentes DJ, Lowes MA, James GK (2011) Resolved psoriasis lesions retain expression of a subset of disease related genes. *J Invest Dermatol* 131(2): 391-400.
3. Nasty A, Smith C, Spurs Pl, Dressler C, Yawalkar N, et al. (2021) EuroGuiDerm guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venerol* 35(2): 281-317.
4. Mantos TR, Malley JT, Lowery EL, Harlan SR, Thomas SK, et al. (2017) Clinically resolved psoriatic lesions contain psoriatic-specific IL-17 producing alpha beta cell clones. *J Clin Invest* 127(11): 4031-4041.
5. Francesco B, Andera C, Stefano P, Targher G, Gisondi P (2022) Could targeted pharmacotherapies exert a 'disease modification effect' in patients with chronic plaque psoriasis. *Int J Mol Sci* 23(21): 12849-12864.
6. Griffiths CEM, Armstrong AW, Godjonsson JE, Jonathan NWN (2021) Psoriasis. *Lancet* 397(10281): 1301-1315.
7. Deane KD, Holers VM (2021) Rheumatoid arthritis pathogenesis, prediction, and prevention: An emerging paradigm shift. *Arthritis Rheumatol* 73(2): 181-193.
8. Berg DR, Colombia JF, Ungaro R (2019) The role of early biologic therapy in inflammatory bowel disease. *Inf Bowel Dis* 25(12): 1896-1905.

